Hokuyaku Takeyama Holdings, Inc operates within the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hokuyaku Takeyama Holdings, Inc with three other
drug stores in Asia:
Jiangsu Nhwa Pharmaceutical Company Limited
sales of 3.02 billion Chinese Renmimbi [US$436.72 million]
of which 55%
was Medical Industrial Manufacturing),
(2.19 billion Malaysian Ringgits [US$494.48 million]
of which 98%
was Logistics and Distribution), and
Huadong Medicine Company Limited
based in China
(25.38 billion Chinese Renmimbi [US$3.67 billion]
of which 79%
During the year ended March of 2016, sales at
Hokuyaku Takeyama Holdings, Inc were ¥225.15 billion (US$2.00 billion).
increase of 6.1%
versus 2015, when the company's sales were ¥212.11 billion.
Sales of Dispensing Business saw an increase
that was more than double the company's growth rate: sales were up
25.8% in 2016, from
¥10.66 billion to ¥13.41 billion.
Hokuyaku Takeyama Holdings, Inc also saw significant increases in sales in
Nursing Care Business (up 15.2% to ¥2.42 billion)
Not all segments of Hokuyaku Takeyama Holdings, Inc experienced an increase in sales in 2016:
sales of Ict Bussiness fell 7.7% to ¥989.00 million.
(However, this segment's sales were only a very small portion of the company's overall sales).
Hokuyaku Takeyama Holdings, Inc also experienced decreases in sales in
Other (down 3.9% to ¥49.00 million)